Dr. Njogu Peter Mbugua obtained his elementary education at Mau-Summit Primary School (1985-1992) and Njoro High School (1993-1996). From September 28th 1998, he studied at the University of Nairobi graduating with a Bachelor of Pharmacy degree on 4th Nov 2002. He worked with the Kenyan Ministry of Health as a pharmacist-intern (Nov 2002-Oct 2003), and as a pharmacist (Nov 2003-Oct 2005). From Oct 2005 to Dec 2007, he studied for Master of Pharmacy in Pharmaceutical Analysis at the University of Nairobi, graduating on 7th Dec 2007. On July 15th 2008, he commenced doctoral studies at the University of Cape Town under the supervision of Prof. Kelly Chibale, graduating with a PhD in Chemistry specialized in Synthetic Medicinal Chemistry on 7th June 2012. Dr. Njogu is currently a lecturer in the Department of Pharmacy, University of Nairobi, where he teaches Pharmaceutical Chemistry at both undergraduate and postgraduate levels. His research interests revolve around drug discovery and development through synthetic medicinal chemistry, computational approaches, formulation design, and phytochemistry, as well as rational use of medicines through pharmaceutical analysis & bioequivalence studies.  

Bio

Njogu, Peter Mbugua

Dr. Njogu Peter Mbugua obtained his elementary education at Mau-Summit Primary School (1985-1992) and Njoro High School (1993-1996). From September 28th 1998, he studied at the University of Nairobi graduating with a Bachelor of Pharmacy degree on 4th Nov 2002. He worked with the Kenyan Ministry of Health as a pharmacist-intern (Nov 2002-Oct 2003), and as a pharmacist (Nov 2003-Oct 2005). From Oct 2005 to Dec 2007, he studied for Master of Pharmacy in Pharmaceutical Analysis at the University of Nairobi, graduating on 7th Dec 2007.

Njogu Peter Mbugua curriculum vitae

Publications


Submitted

Njuru, SN, Njogu PM, Mugo HN, Thoithi GN.  Submitted.  Is tablet splitting a potential pitfall in drug therapy? A case study of amlodipine tablets Pharmaceut. Jour. Kenya.
Degu, A, Mekonnen A, Njogu P.  Submitted.  Treatment outcome among prostate cancer patients in Africa: A systematic review. Prostate Cancer.

2021

Amare, GG, Degu A, Njogu P, Kifle ZD.  2021.  Evaluation of the antimalarial activity of the leaf latex of Aloe weloensis (Aloaceae) against plasmodium parasites. Evid-based Complem. Altern. Med. 2021:6664711.
Mwangi, AN, Njogu PM, Maru SM, Njuguna NM, Njaria PM, Mathenge AW.  2021.  Meloxicam emulgels for topical management of rheumatic diseases: Formulation development, in vitro and in vivo characterization. Saudi Pharmaceut. Jour. 29(4):351–360.

2020

Abuga, KO, Ndwigah SN, Amugune BK, Ongarora DB, Njogu PM, Okaru AO, Kibwage IO.  2020.  Quality control report of drugs analyzed in the Drug Analysis and Research Unit during the period 2011-2015. East Cent. Afr. J. Pharm. Sci. 23(3):79–86.
Kimondo, J, Mutai P, Njogu P, Kimwele C.  2020.  Anti-inflammatory activity of selected plants used by the Ilkisonko Maasai, Kenya. Afr. J. Therapeut. Pharmacol. 9(2):39–43.
Mwangi, M, Tirop L, Njogu P, Bururia J, Mwaura N, Mbae E.  2020.  Formulation of dispersible isoniazid/pyridoxine fixed-dose combination tablets for isoniazid-preventive therapy in paediatrics. Cogent Med. 7(1):1787684.
Kabue, KG, Njogu PM, Mwangi AN.  2020.  Exploring different approaches to improve the success of drug discovery and development projects. Futur. J. Pharm. Sci. 6:27.

2019

Njogu, PM.  2019.  Open Research Referee Report for the article, "Wood-decaying fungi found in Ghana: A rich source of new anti-infective compounds, 06/23. AAS Open Res. :2., Nairobi: African Academy of Sciences
Njogu, P.  2019.  The open peer review model on AAS Open Research is revolutionary. The Africa Academy of Sciences blog.
Omale, JM, Mutai P, Njogu P, Mukungu N, Mwangi J, Odongo E.  2019.  Ethnobotanical survey of antimicrobial medicinal plants used in traditional medicine in western Kenya. Appl. Med. Res. 7(1):6–25.

2018

2017

Degu, A, Njogu P, Weru I, Karimi P.  2017.  Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. Gynecol. Oncol. Res. Pract. 4(15):1–15.
Okombo, J, Singh K, Ndubi F, Barnard L, Wilkson C, Peter M. Njogu, Mireille V, Keiser Jennifer, Egan T, Chibale K.  2017.  Antischistosomal activity of pyrido[1,2-a]benzimidazole derivatives and correlation with inhibition of β-hematin formation. ACS Infect. Dis.. 3:411–420.
Njogu, PM, Okombo J, Chibale K.  2017.  Designed Hybrid Compounds for Tropical Parasitic Diseases. Design of Hybrid Molecules for Drug Development (First Edition). , London: Elsevier
Kawaljit, S, Okombo J, Brunschwig C, Ndubi F, Barnard L, Wilkson C, Njogu PM, Njoroge M, et al.  2017.  Antimalarial pyrido[1,2-a]benzimidazoles: Lead optimization, parasite life cycle stage profile, mechanistic evaluation, killing kinetics and in vivo oral efficacy in a mouse model. J. Med. Chem. 60(4):1432–1448.

2016

Ngumo, PM, Abuga KO, Njogu PM, Ongarora DSB.  2016.  A stability indicating liquid chromatography method for the assay of rufinamide bulk material and tablets. East Cent. Afr. J. Pharm. Sci . 19:16-21.
Njogu, PM, Chibale K.  2016.  Current and Future Strategies for Improving Drug Discovery Efficiency. Attrition in the Pharmaceutical Industry: Reasons, Implications and Pathways Forward. , Hoboken: John Wiley & Sons, Inc

2015

Minyeto, D, Njogu PM, Ndwigah SN, Chepkwony HK.  2015.  Quality and in vitro pharmaceutical equivalence of ciprofloxacin hydrochloride tablets brands in Kenya. East Cent. Afr. J. Pharm. Sci. 18:75–85.2015_minyeto_et_al.pdf
Kimondo, J, Miaron J, Mutai P, Njogu P.  2015.  Ethnobotanical survey of food and medicinal plants of the Ilkisonko Maasai community in Kenya. Journal of Ethnopharmacology. 175 :463–469.

2014

Mungai, NN, Kibwage IO, Mwangi JW, Guantai AN, Njogu PM, Ongarora DSB.  2014.  Isolation, characterization and antiplasmodial activity of phytochemical constituents from Monanthotaxis parvifolia (Oliv.) Verdc ssp. kenyensis Verdc.. East Cent. Afr. J. Pharm. Sci . 17(3):87–93.

2013

Njogu, PM, Gut J, Rosenthal PJ, Chibale K.  2013.  Design, synthesis and antiplasmodial activity of hybrid compounds based on (2R,3S)-N-benzoyl-3-phenylisoserine. ACS Med. Chem. Lett.. 4(7):637-641. Abstract

A series of hybrid compounds based on (2R,3S)-N-benzoyl-3-phenylisoserine, artemisinin and quinoline moieties was synthesized and tested for in vitro antiplasmodial activity against erythrocytic stages of K1 and W2 strains of Plasmodium falciparum. Two hybrid compounds incorporating (2R,3S)-N-benzoyl-3-phenylisoserine and artemisinin scaffolds were three- to four-fold more active than dihydroartemisinin, with nanomolar IC50 values against Plasmodium falciparum K1 strain.

Njogu, PM, Chibale K.  2013.  Recent Developments in Rationally Designed Multitarget Antiprotozoan Agents. Curr. Med. Chem. 20(13):1715-1742. Abstract

Protozoan infections are the leading causes of morbidity and mortality among parasitic infections of humans, accounting for approximately 800 thousand mortalities and a loss of more than 30 million disability-adjusted life years annually. The major protozoan infections of humans, namely malaria, Chagas disease, human African trypanosomiasis, and leishmaniasis, are primarily centered in the tropics, with a reach into some subtropical regions of the world. Though globally massive in their impact, these diseases mostly afflict the least economically endowed and geographically marginalized populations in low-income countries. As such, there is no sufficient market incentive for industrial business-driven antiprotozoal drug discovery due to poor marketing prospects and low returns on investment. Consequently, the pharmacopoeia for majority of these diseases, composed mainly of agents with poor efficacy and unsatisfactory safety profiles, has essentially remained unchanged for decades, creating a compelling need for more efficacious and better tolerated medicines. The policy makers and the scientific community are seeking effective ways to meet this need. So far, two approaches have emerged promising in this regard: combination chemotherapy and drug repositioning. Molecular hybridization has been cited as a potential third approach that could be used to deliver new antiprotozoal chemical entities. In this review article, recent applications of this novel strategy in antimalarial, antichagasic, antitrypanosomal, and antileishmanial drug discovery research and development over the last five years will be presented and discussed.

2012

Njogu, PM, Hendricks DT, Chibale K.  2012.  Hybrids of (2R,3S)-N-benzoyl-3-phenylisoserine and anticancer pharmacophores: Design, synthesis and biological evaluation, 15-18 April. 12th Frank Warren Conference 2012. , Bloemfontein, South Africa

2011

Njogu, PM, Thoithi GN, Mwangi JW, Kamau FN, Kibwage IO, Kariuki ST, Yenesew A, Mugo HN, Mwalukumbi JM.  2011.  Phytochemical and Antimicrobial Investigation of Girardinia diversifolia (Link) Friis (Urticaceae). East Cent. Afr. J. Pharm. Sci. 14(3):89-94. AbstractPhytochemical and Antimicrobial Investigation of Girardinia diversifolia (Link) Friis (Urticaceae)

Root and stem extracts of Girardinia diversifolia exhibited varying degrees of activity against Bacillus pumilus, Staphylococcus aureus, Escherichia coli, Aspergillus niger, Candida albicans and Saccharomyces cerevisiae. Three compounds namely β-sitosterol, 7-hydroxysitosterol and 3-hydroxystigmast-5-en-7-one, were isolated from the petroleum ether root extract. The present study gives scientific credence to the traditional use of Girardinia diversifolia in the management of microbial infections.

UoN Websites Search